Which has better earnings and valuation, STIM or CBLL?

Neuronetics has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.39 -$39M -$0.44 N/A CeriBell $89.06M 10.59 -$53.41M -$1.76 N/A

Is STIM or CBLL more profitable?

Neuronetics has a net margin of -19.62% compared to CeriBell's net margin of -64.73%. CeriBell's return on equity of -44.85% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% CeriBell -64.73% -44.85% -35.69%

Does the media refer more to STIM or CBLL?

In the previous week, CeriBell had 3 more articles in the media than Neuronetics. MarketBeat recorded 4 mentions for CeriBell and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat CeriBell's score of 1.39 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CeriBell 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is STIM or BBNX more profitable?

Neuronetics has a net margin of -19.62% compared to Beta Bionics' net margin of -61.31%. Beta Bionics' return on equity of -26.30% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% Beta Bionics -61.31% -26.30% -23.25%

Does the media prefer STIM or BBNX?

In the previous week, Beta Bionics had 10 more articles in the media than Neuronetics. MarketBeat recorded 11 mentions for Beta Bionics and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat Beta Bionics' score of 0.76 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Beta Bionics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AVR or STIM?

In the previous week, Anteris Technologies Global had 8 more articles in the media than Neuronetics. MarketBeat recorded 9 mentions for Anteris Technologies Global and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat Anteris Technologies Global's score of 0.71 indicating that Neuronetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anteris Technologies Global 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, STIM or INMD?

InMode has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.39 -$39M -$0.44 N/A InMode $370.49M 2.30 $93.83M $1.23 12.07

Is STIM or INMD more profitable?

InMode has a net margin of 20.69% compared to Neuronetics' net margin of -19.62%. InMode's return on equity of 11.99% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% InMode 20.69% 11.99% 10.60%

Does the media prefer STIM or INMD?

In the previous week, InMode had 1 more articles in the media than Neuronetics. MarketBeat recorded 2 mentions for InMode and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat InMode's score of 0.34 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive InMode 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, STIM or SIBN?

SiBone has higher revenue and earnings than Neuronetics. SiBone is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.39 -$39M -$0.44 N/A SiBone $200.93M 4.11 -$18.90M -$0.34 N/A

Is STIM or SIBN more profitable?

SiBone has a net margin of -6.85% compared to Neuronetics' net margin of -19.62%. SiBone's return on equity of -8.23% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% SiBone -6.85% -8.23% -6.07%

Does the media prefer STIM or SIBN?

In the previous week, SiBone had 4 more articles in the media than Neuronetics. MarketBeat recorded 5 mentions for SiBone and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat SiBone's score of 0.79 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SiBone 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neuronetics (STIM) Competitors

$2.72 -0.05 (-1.81%)

As of 09/3/2026 04:00 PM Eastern

Compare

STIM vs. CBLL, BBNX, AVR, INMD, and SIBN

Should you buy Neuronetics stock or one of its competitors? Neuronetics's main competitors and comparable companies include CeriBell (CBLL), Beta Bionics (BBNX), Anteris Technologies Global (AVR), InMode (INMD), and SiBone (SIBN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Neuronetics compare to CeriBell?

Neuronetics (NASDAQ:STIM) and CeriBell (NASDAQ:CBLL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Neuronetics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Neuronetics has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.39	-$39M	-$0.44	N/A
CeriBell	$89.06M	10.59	-$53.41M	-$1.76	N/A

In the previous week, CeriBell had 3 more articles in the media than Neuronetics. MarketBeat recorded 4 mentions for CeriBell and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat CeriBell's score of 1.39 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CeriBell	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neuronetics currently has a consensus target price of $4.50, suggesting a potential upside of 65.44%. CeriBell has a consensus target price of $24.40, suggesting a potential downside of 0.69%. Given Neuronetics' higher possible upside, analysts plainly believe Neuronetics is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Comparatively, 17.7% of CeriBell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Neuronetics has a net margin of -19.62% compared to CeriBell's net margin of -64.73%. CeriBell's return on equity of -44.85% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
CeriBell	-64.73%	-44.85%	-35.69%

Summary

Neuronetics beats CeriBell on 10 of the 17 factors compared between the two stocks.

How does Neuronetics compare to Beta Bionics?

Neuronetics (NASDAQ:STIM) and Beta Bionics (NASDAQ:BBNX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Neuronetics currently has a consensus price target of $4.50, suggesting a potential upside of 65.44%. Beta Bionics has a consensus price target of $20.10, suggesting a potential upside of 0.90%. Given Neuronetics' higher probable upside, equities research analysts clearly believe Neuronetics is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Neuronetics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.37, indicating that its stock price is 237% more volatile than the broader market.

Neuronetics has a net margin of -19.62% compared to Beta Bionics' net margin of -61.31%. Beta Bionics' return on equity of -26.30% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
Beta Bionics	-61.31%	-26.30%	-23.25%

53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Neuronetics has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.39	-$39M	-$0.44	N/A
Beta Bionics	$100.25M	8.94	-$73.20M	-$1.65	N/A

In the previous week, Beta Bionics had 10 more articles in the media than Neuronetics. MarketBeat recorded 11 mentions for Beta Bionics and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat Beta Bionics' score of 0.76 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Beta Bionics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neuronetics beats Beta Bionics on 10 of the 15 factors compared between the two stocks.

How does Neuronetics compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Neuronetics has a net margin of -19.62% compared to Anteris Technologies Global's net margin of -4,619.27%. Anteris Technologies Global's return on equity of -77.69% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-4,619.27%	-77.69%	-67.99%
Neuronetics	-19.62%	-125.11%	-22.15%

Anteris Technologies Global has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Neuronetics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

In the previous week, Anteris Technologies Global had 8 more articles in the media than Neuronetics. MarketBeat recorded 9 mentions for Anteris Technologies Global and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat Anteris Technologies Global's score of 0.71 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anteris Technologies Global	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Neuronetics has higher revenue and earnings than Anteris Technologies Global. Neuronetics is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	444.95	-$94.14M	-$1.95	N/A
Neuronetics	$149.16M	1.39	-$39M	-$0.44	N/A

Anteris Technologies Global presently has a consensus price target of $16.00, suggesting a potential upside of 83.49%. Neuronetics has a consensus price target of $4.50, suggesting a potential upside of 65.44%. Given Anteris Technologies Global's stronger consensus rating and higher possible upside, equities research analysts plainly believe Anteris Technologies Global is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

53.6% of Neuronetics shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by company insiders. Comparatively, 8.4% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Anteris Technologies Global and Neuronetics tied by winning 8 of the 16 factors compared between the two stocks.

How does Neuronetics compare to InMode?

Neuronetics (NASDAQ:STIM) and InMode (NASDAQ:INMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

In the previous week, InMode had 1 more articles in the media than Neuronetics. MarketBeat recorded 2 mentions for InMode and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat InMode's score of 0.34 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
InMode	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Comparatively, 6.9% of InMode shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

InMode has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.39	-$39M	-$0.44	N/A
InMode	$370.49M	2.30	$93.83M	$1.23	12.07

InMode has a net margin of 20.69% compared to Neuronetics' net margin of -19.62%. InMode's return on equity of 11.99% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
InMode	20.69%	11.99%	10.60%

Neuronetics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, InMode has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market.

Neuronetics currently has a consensus price target of $4.50, suggesting a potential upside of 65.44%. InMode has a consensus price target of $16.00, suggesting a potential upside of 7.82%. Given Neuronetics' stronger consensus rating and higher probable upside, analysts plainly believe Neuronetics is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

InMode beats Neuronetics on 11 of the 16 factors compared between the two stocks.

How does Neuronetics compare to SiBone?

Neuronetics (NASDAQ:STIM) and SiBone (NASDAQ:SIBN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

SiBone has higher revenue and earnings than Neuronetics. SiBone is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.39	-$39M	-$0.44	N/A
SiBone	$200.93M	4.11	-$18.90M	-$0.34	N/A

In the previous week, SiBone had 4 more articles in the media than Neuronetics. MarketBeat recorded 5 mentions for SiBone and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat SiBone's score of 0.79 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
SiBone	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neuronetics presently has a consensus target price of $4.50, indicating a potential upside of 65.44%. SiBone has a consensus target price of $24.17, indicating a potential upside of 29.65%. Given Neuronetics' higher possible upside, equities analysts plainly believe Neuronetics is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Neuronetics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

SiBone has a net margin of -6.85% compared to Neuronetics' net margin of -19.62%. SiBone's return on equity of -8.23% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
SiBone	-6.85%	-8.23%	-6.07%

Summary

SiBone beats Neuronetics on 11 of the 16 factors compared between the two stocks.

Get Neuronetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STIM vs. The Competition

Export

Metric	Neuronetics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$211.07M	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	-6.18	25.92	273.29	25.38
Price / Sales	1.39	73.28	613.45	97.56
Price / Cash	N/A	33.14	77.82	52.26
Price / Book	9.71	6.04	12.89	6.14
Net Income	-$39M	$150.03M	$3.47B	$349.01M
7 Day Performance	-7.48%	-1.32%	0.60%	-0.27%
1 Month Performance	18.26%	1.28%	5.73%	0.68%
1 Year Performance	-17.82%	9.88%	25.35%	14.84%

Neuronetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STIM Neuronetics	4.0344 of 5 stars	$2.72 -1.8%	$4.50 +65.4%	-16.8%	$211.07M	$149.16M	N/A	180	Positive News
CBLL CeriBell	1.4268 of 5 stars	$23.62 +1.1%	$22.40 -5.2%	+111.6%	$906.54M	$89.06M	N/A	N/A	Positive News Analyst Forecast
BBNX Beta Bionics	1.3345 of 5 stars	$19.60 +0.3%	$20.10 +2.6%	+1.2%	$881.80M	$100.25M	N/A	294	News Coverage Insider Trade
AVR Anteris Technologies Global	2.7388 of 5 stars	$8.85 -1.3%	$16.00 +80.8%	+112.7%	$862.50M	$2.24M	N/A	138	Positive News
INMD InMode	1.367 of 5 stars	$14.85 +0.1%	$16.00 +7.7%	+2.3%	$853.59M	$374.63M	12.07	480

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STIM) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neuronetics (STIM) Competitors

STIM vs. CBLL, BBNX, AVR, INMD, and SIBN

How does Neuronetics compare to CeriBell?

Summary

How does Neuronetics compare to Beta Bionics?

Summary

How does Neuronetics compare to Anteris Technologies Global?

Summary

How does Neuronetics compare to InMode?

Summary

How does Neuronetics compare to SiBone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neuronetics (STIM) Competitors

STIM vs. CBLL, BBNX, AVR, INMD, and SIBN

How does Neuronetics compare to CeriBell?

Which has more risk and volatility, STIM or CBLL?

Which has better earnings and valuation, STIM or CBLL?

Does the media refer more to STIM or CBLL?

Do analysts recommend STIM or CBLL?

Do institutionals & insiders hold more shares of STIM or CBLL?

Is STIM or CBLL more profitable?

Summary

How does Neuronetics compare to Beta Bionics?

Do analysts recommend STIM or BBNX?

Which has more volatility & risk, STIM or BBNX?

Is STIM or BBNX more profitable?

Do insiders and institutionals hold more shares of STIM or BBNX?

Which has preferable earnings & valuation, STIM or BBNX?

Does the media prefer STIM or BBNX?

Summary

How does Neuronetics compare to Anteris Technologies Global?

Is AVR or STIM more profitable?

Which has more risk & volatility, AVR or STIM?

Does the media refer more to AVR or STIM?

Which has stronger valuation & earnings, AVR or STIM?

Do analysts prefer AVR or STIM?

Do insiders and institutionals have more ownership in AVR or STIM?

Summary

How does Neuronetics compare to InMode?

Does the media prefer STIM or INMD?

Do insiders & institutionals hold more shares of STIM or INMD?

Which has preferable earnings and valuation, STIM or INMD?

Is STIM or INMD more profitable?

Which has more risk & volatility, STIM or INMD?

Do analysts recommend STIM or INMD?

Summary

How does Neuronetics compare to SiBone?

Which has better valuation & earnings, STIM or SIBN?

Does the media prefer STIM or SIBN?

Do institutionals and insiders believe in STIM or SIBN?

Do analysts prefer STIM or SIBN?

Which has more risk and volatility, STIM or SIBN?

Is STIM or SIBN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools